|

Universal Donor Expanded TGF-beta-imprinted NK Cells Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Allogeneic TGFBi Expanded NK Cells, UD TGF-betai NK Cells, Universal Donor TGF-beta Imprinted Expanded NK Cells

Pipeline

Early 1: 1Phase 1/2: 1

Top Sponsors

  • Margaret Gatti-Mays1
  • Kirsten Johnson1

Indications

  • Cancer2
  • Skin Nodular Basal Cell Carcinoma1
  • Skin Squamous Cell Carcinoma1
  • Skin Basal Cell Carcinoma1
  • Anatomic Stage IV Breast Cancer AJCC v81

Columbus, Ohio2 trials

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Ohio State University Comprehensive Cancer Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.